STOCKHOLM, Sweden, Sept. 16, 2003 (PRIMEZONE) -- With reference to today's press release regarding results from Phase II study of Active Biotech's (Other OTC:ACTBF) laquinimod (SAIK-MS), we hereby invites to a teleconference today, Tuesday 16 September at 11:00 CET.To participate in the teleconference, please call +44 207 162 0192.
To listen at the teleconference please visit www.activebiotech.com.
To listen to the teleconference afterwards, please call +44 20 8288 4459, password 526992 and/or visit www.activebiotech.com.
Active Biotech AB is a biotechnology company focusing on research in and development of pharmaceuticals. Active Biotech has a strong R&D portfolio and pipeline products with focus primarily on autoimmune/inflammatory diseases and cancer. Most advanced projects include orally administered small molecules with unique immunomodulatory properties that can be used to treat autoimmune and inflammatory diseases (SAIK), as well as a novel concept for use in cancer immunotherapy (TTS).